Nr 546 adhd medication table / nr 546 Study guides, Study notes & Summaries

Chamberlain NR 546 Week 7 ADHD Medication Table

NR 546 WEEK 7 ADHD Medication Table (Updated). Methylphenidate (D/L) (Concerta, Ritalin) -Dopamine, norepinephrine inhibitor and releaser (DNRIRe), stimulant, FDA approved for ADHD in children and adults (ages vary based on formulations), narcolepsy. Off-label for treatmentresistant depression. Enhancement DA and NE in certain areas of the brain (dorsolateral prefrontal cortex, medial prefrontal cortex). Primary target symptoms: concentration, attention span, motor hyperactivity,...

NR 546 Week 7 ADHD Medication Table Latest. Drug Name (include if IR, XR, ODT, LA) Indication (include approved ages) Neurotransmitter(s) Affected Target Symptoms Short-acting, intermediate-acting or long-acting. Duration of action, peak (if noted) Notable side effects /Patient education instructions Methylphenidate (D/L) (Concerta, Ritalin) Indication (include approved ages) Attention deficit hyperactivity disorder (ADHD) in children and adults (approved ages vary base...

NR 546 Week 7 ADHD Medication Table Latest. Drug Name (include if IR, XR, ODT, LA) Indication (include approved ages) Neurotransmitter(s) Affected Target Symptoms Short-acting, intermediate-acting or long-acting. Duration of action, peak (if noted) Notable side effects /Patient education instructions Methylphenidate (D/L) (Concerta, Ritalin) Indication (include approved ages) Attention deficit hyperactivity disorder (ADHD) in children and adults (approved ages vary base...

NR 546 WEEK 7 ADHD Medication Table. Drug Name (include if IR, XR, ODT, LA) Indication (include approved ages) Neurotransmitter(s) Affected Target Symptoms Short-acting, intermediateacting or long-acting. Duration of action, peak (if noted) Notable side effects /Patient education instructions Methylphenidate (D/L) (Concerta, Ritalin) -Dopamine, norepinephrine inhibitor and releaser (DNRIRe), stimulant, FDA approved for ADHD in children and adults (ages vary based on formulatio...

Drug Name (include if IR, XR, ODT, LA) Indication (include approved ages) Neurotransmitter(s) Affected Target Symptoms Short-acting, intermediateacting or long-acting. Duration of action, peak (if noted) Notable side effects /Patient education instructions Methylphenidate (D/L) (Concerta, Ritalin) -Dopamine, norepinephrine inhibitor and releaser (DNRIRe), stimulant, FDA approved for ADHD in children and adults (ages vary based on formulations), narcolepsy. Off-label for trea...

NR 546 Week 7 ADHD Medication Table / NR 546 Week 7 ADHD Medication Table Latest UPDATE 2024 GRADED A+.

NR 546 Midterm Exam 2023/2024 Questions AND Answers Update A+ What should the PMHNP consider when prescribing chemical restraints? - Answer-- allergy status -prior med hx for adverse drug reactions r/t the meds ordered in the chemical restraint -state regulations regarding chemical restrains must be reviewed Are the PMHNP and other staff liable if the client has an allergic reaction or adverse side effects to the drugs used for chemical restraint? - Answer-No. The client has been court-...